| P/E (FY) | — | Sales (TTM) | $31,000 |
| Earnings (TTM) | -$246.4M | ROE | −86.98% |
| Net Margin | −762355.56% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −92.48% |
| Market Cap | $303.1M | Trading Days | 941 |
| 52W High | 45.00 |
| 52W Low | 9.28 |
| % Off High | −71.13% |
| YTD | −57.80% | 1Y | −5.39% |
| 3Y | −77.91% | Since incept. (ann.) | −46.06% |
Reportable 100%
| Ann. Volatility (1Y) | 81.72% | Ann. Volatility (3Y) | 100.78% |
| Sharpe (1Y) | 0.33 | Sharpe (3Y) | −0.00 |
| Max Drawdown (1Y) | −69.92% | Max Drawdown (3Y) | −87.30% |
| Beta (3Y, vs SPY) | 1.85 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $301.2M | — |
| VNDA | Vanda Pharmaceuticals Inc. | $310.3M | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $282.5M | — |
| ORGO | Organogenesis Holdings Inc. | $325.5M | 16.9 |
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| CATX | Perspective Therapeutics, Inc. | $327.3M | — |
| FBIO | Fortress Biotech, Inc. | $279.6M | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $328.9M | — |
| IRD | Opus Genetics, Inc. | $277.6M | — |
| RMTI | ROCKWELL MEDICAL, INC. | $275.9M | — |
| BCYC | BICYCLE THERAPEUTICS PLC |
| $273.0M |
| — |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
